Claimant scorecard · AERS v2.1 · Calibrating
Roche
1 claim tracked in the Responsibility Ledger. 1 pending grade.
AERS
—
Insufficient closed grades
Pending
1
Open horizons
Closed
0
Graded outcomes
First tracked
Sep 29, 2026
Open horizons
Roche: Target Nexus AI tool will contribute to 80% of research portfolio decisions by the end of 2026, and the company will bring up to 20 new molecular entities to market by 2030
About this scorecard
The AI Execution Risk Score (AERS) is a 0-100 metric quantifying the gap between Roche’s public AI claims and demonstrated delivery. Higher AERS = stronger track record. Each claim above is drawn from a primary source linked in the original Ledger entry; the horizon date is when the claim becomes graded under the published methodology. Materiality is the editor’s assessment of the claim’s formality from 1 (PR statement) to 5 (earnings call or SEC filing).
AERS v2.1 · Methodology in active calibration · Not investment advice.